GlassScriptPhysician profile
Marc Robert Labbe
NPI 1306889886
$237,701.45
in general payments reported to CMS, 2019-2025
15 companies · $18K in 2025
The $18K reported for 2025 was more than what 90% of Sports Medicine (Orthopaedic Surgery) providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73K · 2020: $30K · 2021: $29K · 2022: $23K · 2023: $15K · 2024: $51K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $63K · Travel and Lodging: $13K · Food and Beverage: $3,947 · Royalty Or License: $2,387 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $62,998.17 |
| Travel and Lodging | $12,508.61 |
| Food and Beverage | $3,947.26 |
| Royalty Or License | $2,386.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $113,562.83 | 2019-2025 | Inhance, Mitek, Dynacord |
| Smith+Nephew, INC. | $65,609.17 | 2019-2023 | Bioinductive Implant With Arthroscopic Delivery System - Medium, Healicoil, Stravix Pl |
| Depuy Synthes Products, INC. | $43,432.09 | 2019-2024 | Fms |
| Integrity Orthopaedics, INC. | $11,713.48 | 2024-2025 | Integrity Orthopaedics |
| Briohealth Solutions, INC. | $2,100.00 | 2025 | Briovad |
| Depuy Synthes Sales INC. | $811.40 | 2019-2025 | Healix Knotless Peek, Orthovisc, Monovisc |
| Bioventus LLC | $155.69 | 2023-2025 | Durolane, Durolane, Xcell |
| Becton, Dickinson and Company | $89.39 | 2024 | Channel Drain |
| Fx Shoulder Solutions, INC | $81.11 | 2022 | |
| Pacira Therapeutics, INC. | $57.02 | 2020 | |
| Davol INC. | $20.88 | 2025 | Channel Drain |
| Vericel Corporation | $18.92 | 2024 | Maci |
| Ferring Pharmaceuticals INC. | $17.54 | 2022 | |
| Catalyst Orthoscience | $17.47 | 2021 | |
| Xiros INC | $14.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,225,296.78 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Labbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.